Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms

AAPS Journal

Volumn 14, Issue 3, 2012, Pages 500-509

  Finley, Stacey D ^a   Popel, Aleksander S ^a  

^a Johns Hopkins University   (United States)

Author keywords

angiogenesis; cancer drug target; computational model; pharmacokinetic model; systems biology

Indexed keywords

NEUROPILIN 1; NEUROPILIN 2; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST TUMOR; COMPARTMENT MODEL; COMPLEX FORMATION; CONCENTRATION PROCESS; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; GENE OVEREXPRESSION; MOLECULAR MODEL; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PROTEIN TRANSPORT; SIMULATION; TISSUE LEVEL; TRANSPORT KINETICS;

ALTERNATIVE SPLICING; ANGIOGENESIS INHIBITORS; HUMANS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862768329     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9363-4     Document Type: Article

References (48)

1. ES Rennel SJ Harper DO Bates 2009 Therapeutic potential of manipulating VEGF splice isoforms in oncology Futur Oncol 5 5 703 712 10.2217/fon.09.33 1:CAS:528:DC%2BD1MXnt1Gjsb8%3D
2. DO Bates T-G Cui JM Doughty M Winkler M Sugiono JD Shields, et al. 2002 VEGF165b, and inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma Cancer Res 62 4123 4131 12124351 1:CAS:528:DC%2BD38XlsV2ltrw%3D
3. DG Nowak J Woolard EM Amin O Konopatskaya MA Saleem AJ Churchill, et al. 2008 Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors J Cell Sci. 121 3487 3495 18843117 10.1242/jcs.016410 1:CAS:528:DC%2BD1cXhsVaitLbI
4. AO Dokun BH Annex 2011 The VEGF165b "ICE-o-form" puts a chill on the VEGF story Circul Res. 109 246 247 10.1161/CIRCRESAHA.111.249953 1:CAS:528:DC%2BC3MXpt1KlsLY%3D
5. M Manetti S Guiducci E Romano C Ceccarelli S Bellando-Randone ML Conforti, et al. 2011 Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis Circul Res. 109 e14 e26 10.1161/CIRCRESAHA.111. 242057 1:CAS:528:DC%2BC3MXpt1Kltr4%3D
6. R Catena L Larzabal M Larrayoz E Molina J Hermida J Agorreta, et al. 2010 VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A Molecular Cancer. 9 320 21194429 10.1186/1476-4598-9-320 1:CAS:528:DC%2BC3MXpt1ahtA%3D%3D
7. S Soker H-Q Miao M Nomi S Takashima M Klagsbrun 2002 VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding J Cell Biochem 85 2 357 368 11948691 10.1002/jcb.10140 1:CAS:528:DC%2BD38XivVyqs78%3D
8. G Fuh KC Garcia AM De Vos 2000 The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1 J Biol Chem 275 26690 26695 10842181 1:CAS:528:DC%2BD3cXmsVWrtL8%3D
9. JE Park G-A Keller N Ferrara 1993 The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF Mol Biol Cell. 4 1317 1326 8167412 1:CAS:528:DyaK2cXitlOjur0%3D
10. K Houck DW Leung AM Rowland J Winer N Ferrara 1992 Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms J Biol Chem 268 36 26031 26037
11. J Grunstein JJ Masbad R Hickey F Giordano RS Johnson 2000 Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature Mol Cell Biol 20 19 7292 1 10.1128/MCB.20.19.7282-7291. 2000
12. GM Tozer S Akerman NA Cross PR Barber MA Bjorndahl O Greco, et al. 2008 Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors Cancer Res 68 2301 2311 18381437 10.1158/0008-5472.CAN-07-2011 1:CAS:528:DC%2BD1cXktVyqu7c%3D
13. JL Yu JW Rak G Klement RS Kerbel 2002 Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts Cancer Res 62 1838 1846 11912163 1:CAS:528:DC%2BD38XisVSit7o%3D
14. A Yuan C-J Yu S-H Kuo W-J Chen F-Y Lin K-T Luh, et al. 2001 Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer J Clin Oncol 19 2 432 441 11208836 1:CAS:528:DC%2BD3MXhtVekt7Y%3D
15. S-Y Cheng M Nagane H-JS Huang WK Cavenee 1997 Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189 Proc Natl Acad Sci U S A 94 22 12081 12087 9342366 10.1073/pnas.94.22.12081 1:CAS:528: DyaK2sXntFSmtro%3D
16. A Yuan C-Y Lin C-H Chou C-M Shih C-Y Chen H-W Cheng, et al. 2011 Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI PLoS One 6 1 e16062 21283766 10.1371/journal.pone.0016062 1:CAS:528:DC%2BC3MXht1Ogsbk%3D
17. T Tokunaga Y Oshika Y Abe Y Ozeki S Sadahiro H Kijima, et al. 1998 Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer Br J Cancer 77 6 998 1002 9528847 10.1038/bjc.1998.164 1:STN:280:DyaK1c7oslKqtA%3D%3D
18. BM Fenton SF Paoni W Liu S-Y Cheng B Hu I Ding 2004 Overexpression of VEGF121, but not VEGF165 or FGF-1, improves oxygenation in MCF-7 breast tumors Br J Cancer 90 2 430 435 14735189 10.1038/sj.bjc.6601539 1:CAS:528: DC%2BD2cXksl2ltQ%3D%3D
19. JJC Verhoeff LJA Stalpers A Claes KE Hovinga GD Musters WP Vandertop, et al. 2009 Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma Eur J Cancer 45 17 3074 3080 19734041 10.1016/j.ejca.2009.08.004 1:CAS:528:DC%2BD1MXhtlyjsbbE
20. J Ruckman LS Green J Beeson S Waugh WL Gillette DD Henninger, et al. 1998 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain J Biol Chem 273 20556 20567 9685413 10.1074/jbc.273.32.20556 1:CAS:528:DyaK1cXlsVWgu70%3D
21. EWM Ng DT Shima P Calias ET Cunningham Jr DR Guyer AP Adamis 2006 Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease Nat Rev Drug Discov. 5 123 132 16518379 10.1038/nrd1955 1:CAS:528:DC%2BD28Xhslaqur8%3D
22. S Ishida T Usui K Yamashiro Y Kaji S Amano Y Ogura, et al. 2003 VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization J Exp Med. 198 3 483 489 12900522 10.1084/jem.20022027 1:CAS:528:DC%2BD3sXmt1Ggsrg%3D
23. DK Arrell A Terzic 2010 Network systems biology for drug discovery Clin Pharmacol Ther 8 1 120 125 10.1038/clpt.2010.91
24. R Laubenbacher V Hower A Jarrah SV Torti V Shulaev P Mendes, et al. 2009 A systems biology view of cancer Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1796 2 129 139 10.1016/j.bbcan.2009.06.001 1:CAS:528: DC%2BD1MXhtFyqsLjE
25. SD Finley MO Engel-Stefanini PI Imoukhuede AS Popel 2011 Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies BMC Syst Biol 5 193 22104283 10.1186/1752-0509-5-193 1:CAS:528:DC%2BC38XisV2nsrY%3D
26. MO Stefanini FTH Wu F Mac Gabhann AS Popel 2010 Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model Cancer Res 70 23 9886 9894 21118974 10.1158/0008-5472.CAN- 10-1419 1:CAS:528:DC%2BC3cXhsFamurjI
27. TP Padera A Kadambi E Di Tomaso CM Carreira EB Brown Y Boucher, et al. 2002 Lymphatic metastasis in the absence of functional intratumor lymphatics Science 296 5574 1883 1886 11976409 10.1126/science.1071420 1:CAS:528: DC%2BD38XksVWnu7s%3D
28. AJ Leu DA Berk A Lymboussaki K Alitalo RK Jain 2000 Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation Cancer Res 60 4324 4327 10969769 1:CAS:528:DC%2BD3cXmsVaitbk%3D
29. PI Imoukhuede AS Popel 2011 Quantification and cell-to-cell variation of vascular endothelial growth factor receptors Exp Cell Res. 317 7 955 965 21185287 10.1016/j.yexcr.2010.12.014 1:CAS:528:DC%2BC3MXjtFOns74%3D
30. Genentech, Inc. Avastin prescribing information [cited September2011]; Available from: http://www.avastin.com/avastin/hcp/overview/about/dosing/index. html.
31. MS Gordon K Margolin M Talpaz GW Sledge Jr E Holmgren R Benjamin, et al. 2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 3 843 850 11157038 1:CAS:528:DC%2BD3MXhtlGrt7k%3D
32. V Hsei GG DeGuzman A Nixon J Gaudreault 2002 Complexation of VEGF with bevacizumab decreases VEGF clearance in rats Pharm Res 19 11 1753 1756 12458683 10.1023/A:1020778001267 1:CAS:528:DC%2BD38XotV2gs74%3D
33. W-C Liang X Wu FV Peale CV Lee YG Meng J Gutierrez, et al. 2006 Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF J Biol Chem 281 951 961 16278208 10.1074/jbc.M508199200 1:CAS:528:DC%2BD28Xit1Witw%3D%3D
34. P Guo L Xu S Pan RA Brekken S-T Yang GB Whitaker, et al. 2001 Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites Cancer Res 61 8569 8577 11731444 1:CAS:528:DC%2BD3MXptFCku7w%3D
35. R Catena V Muniz-Medina B Moralejo B Javierre CJM Best MR Emmert-Buck, et al. 2007 Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis Int J Cancer 120 2096 2109 17278099 10.1002/ijc.22461 1:CAS:528:DC%2BD2sXkt1Oitbg%3D
36. H-T Zhang PAE Scot L Morbidelli S Peak J Moore H Turley, et al. 2000 The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo Br J Cancer 83 1 63 68 10883669 10.1054/bjoc.2000.1279 1:CAS:528:DC%2BD3cXkvFOgsbc%3D
37. M Stimpfl D Tong B Fasching E Schuster A Obermair S Leodolter, et al. 2002 Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer Clin Cancer Res 8 7 2253 2259 12114428 1:CAS:528:DC%2BD38XmtVWhs70%3D
38. A Yuan CJ Yu KT Luh FY Lin SH Kuo PC Yang 2000 Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR Lab Invest. 2000 80 11
39. N Cheung MP Wong ST Yuen SY Leung LP Chung 1998 Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon Hum Pathol 29 9 910 914 9744306 10.1016/S0046-8177(98)90195-2 1:CAS:528:DyaK1cXmtlyks7w%3D
40. B Ljungberg J Jacobsen S Haggstrom-Rudolfssson T Rasmuson G Lindh K Grankvist 2003 Tumor vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma Urol Res 31 5 335 340 14574539 10.1007/s00240-003-0346-x 1:CAS:528:DC%2BD3sXot1Oqtrg%3D
41. E Zygalaki EG Tsaroucha L Kaklamanis ES Lianidou 2007 Quantitative real-time reverse transcription-PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non-small cell lung cancer Clin Chem 53 8 1433 1439 17599955 10.1373/clinchem.2007.086819 1:CAS:528:DC%2BD2sXosVKqs7k%3D
42. K Hata Y Watanabe H Nakai T Hata H Hoshiai 2011 Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF therapy Anticancer Res 31 2 731 737 21378364 1:CAS:528:DC%2BC3MXksFWkt78%3D
43. H Wiig O Tenstad PO Iversen R Kalluri R Bjerkvig 2010 Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair. 3 12 20653943 10.1186/1755-1536-3-12
44. J Huang J Moore S Soffer E Kim D Rowe CA Manley, et al. 2001 Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors J Pediatr Surg 36 357 361 11172434 10.1053/jpsu.2001.20716 1:STN:280:DC%2BD3MzjslGmtQ%3D%3D
45. JH Chidlow Jr JD Glawe CB Pattillo S Pardue S Zhang CG Kevil 2011 VEGF164 isoform specific regulation of T-cell-dependent experimental colitis in mice Inflamm Bowel Dis. 17 1501 1512 21674706 10.1002/ibd.21525
46. O Sawada H Kawamura M Kakinoki T Sawada M Ohji 2007 Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy Arch Ophthalmol 125 10 1363 1366 17923544 10.1001/archopht.125.10.1363 1:CAS:528:DC%2BD2sXht1aqurrP
47. XJ Tian J Wu L Meng ZW Dong CC Shou 2000 Expression of VEGF121 in gastric carcinoma MGC803 cell line World J Gastroenterol 6 2 281 283 1:CAS:528:DC%2BD3cXjtFahs7o%3D
48. P Guo Q Fang H-Q Tao CA Schafer BM Fenton I Ding, et al. 2003 Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo Cancer Res 63 4684 4691 12907650 1:CAS:528:DC%2BD3sXmtFersbg%3D